N
CYTK icon

Natixis’s Cytokinetics CYTK Stock Holding History

Natixis’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-315,831
Closed -$26.4M – 1050
2023
Q4 		$26.4M Buy
+315,831
New +$11.4M 0.19% 113
2023
Q1 		– Sell
-1,602
Closed -$73.4K – 1032
2022
Q4 		$73.4K Buy
+1,602
New +$68.9K ﹤0.01% 897
2014
Q1 		– Sell
-11,300
Closed -$75K – 539
2013
Q4 		$75K Buy
+11,300
New +$74.2K ﹤0.01% 516

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Natixis's CYTK Position: Q1 2024 in Review

Natixis sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 315,831 shares — an estimated $26.4M sold.

Natixis first reported a position in CYTK in Q4 2013 and held it in 3 quarters. The position peaked at $26.4M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Natixis reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 315,831 Cytokinetics shares in Q1 2024, an estimated $26.4M.
  • Natixis first reported a position in Cytokinetics in Q4 2013 and held it in 3 quarters.
  • Natixis's Cytokinetics position peaked at $26.4M in Q4 2023.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.